Advancement in antithrombotics for stroke prevention in atrial fibrillation (original) (raw)

Another oral thrombin inhibitor for stroke prevention in atrial fibrillation?

Jeffrey Weitz

Thrombosis and Haemostasis, 2010

View PDFchevron_right

Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban

Tang Kok Foo

Thrombosis, 2012

View PDFchevron_right

New Oral Anticoagulants in Atrial Fibrillation Forever?

Jeffrey Weitz

Circulation, 2013

View PDFchevron_right

New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation

GUALTIERO PALARETI

Journal of Internal Medicine, 2012

View PDFchevron_right

Emerging therapies for stroke prevention in atrial fibrillation

Jeffrey Weitz

European Heart Journal Supplements, 2005

View PDFchevron_right

Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants

João Morais

Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy, 2016

View PDFchevron_right

Novel anticoagulants in atrial fibrillation stroke prevention

Nicholas Norgard

Therapeutic advances in chronic disease, 2012

View PDFchevron_right

New Anticoagulants for Atrial Fibrillation

Giulia Renda

Seminars in Thrombosis and Hemostasis, 2009

View PDFchevron_right

Old and new oral anticoagulants for secondary stroke prevention in atrial fibrillation

Gaetano Procaccianti

Italian Journal of Medicine, 2015

View PDFchevron_right

Dabigatran and other oral antithrombotic agents for the prevention of stroke in patients with atrial fibrillation

Fernando Testai

Research Reports in Clinical Cardiology, 2011

View PDFchevron_right

Stroke Prevention in Atrial Fibrillation: Current Status and Near-Future Directions

Sarah Hussain

The American Journal of Medicine, 2011

View PDFchevron_right

Rivaroxaban—Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study

Graeme Hankey

American Heart Journal, 2010

View PDFchevron_right

Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation

Anil Chauhan

Postgraduate Medical Journal, 2005

View PDFchevron_right

Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence

gerardo nigro

Therapeutic Advances in Drug Safety, 2016

View PDFchevron_right

Prevention of stroke in patients with atrial fibrillation: current strategies and future directions

Gabor Duray

European Heart Journal Supplements, 2008

View PDFchevron_right

Stroke Prevention in Atrial Fibrillation: Managing the Risks in Light of New Oral Anticoagulants

John Strobeck

Cardiovascular Drugs and Therapy, 2012

View PDFchevron_right

Novel antithrombotic agents for atrial fibrillation

Vias Markides, Diana Gorog

Pharmacology & Therapeutics, 2012

View PDFchevron_right

Dabigatran and Factor Xa Inhibitors for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation

Masayasu Matsumoto

Journal of Stroke and Cerebrovascular Diseases, 2012

View PDFchevron_right

Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non–Vitamin K Antagonist Oral Anticoagulants

Joris Komen

Stroke, 2018

View PDFchevron_right

Newer Anticoagulants for Atrial Fibrillation: the Role of Dabigatran, Rivaroxaban, Apixaban and Edoxaban / RELY, ROCKET-AF, ARISTOTLE, & ENGAGE AF TIMI 48 Studies/ Safety Issues

Sokratis Pastromas

View PDFchevron_right

Anticoagulant Therapy in Atrial Fibrillation – Time for a Change?

Giulia Renda

European Cardiology Review, 2009

View PDFchevron_right

Antithrombotic Therapy for Atrial Fibrillation

Mark Eckman

Chest, 2012

View PDFchevron_right

Anticoagulation Strategies in Atrial Fibrillation

Sammy Khatib

Reviews in Cardiovascular Medicine, 2012

View PDFchevron_right

Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: A Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy

Karin Wåhlander

Thrombosis Research, 2011

View PDFchevron_right

Relative effects of different non-vitamin K antagonist oral anticoagulants on global thrombotic status in atrial fibrillation

Mohamed Farag

Platelets, 2016

View PDFchevron_right

Antithrombotic therapy in nonvalvular atrial fibrillation: A narrative review

Francisco Rocha-Gonçalves

Revista Portuguesa de Cardiologia, 2011

View PDFchevron_right

Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: Focus on Apixaban

Scott Yates

Advances in Therapy, 2012

View PDFchevron_right

Novel oral anticoagulants in atrial fibrillation: will the benefit outweigh the cost?

Athanasios Pipilis

Hellenic Journal of Cardiology, 2012

View PDFchevron_right

The Role of Nonvitamin K Antagonist Oral Anticoagulants (NOACs) in Stroke Prevention in Patients with Atrial Fibrillation

Can Gönen

Current neurology and neuroscience reports, 2016

View PDFchevron_right

Prevention of Stroke in Patients with Atrial Fibrillation: The Role of New Antiarrhythmic and Antithrombotic Drugs

Maciej Kluk

Cerebrovascular Diseases, 2010

View PDFchevron_right

Stroke Prevention Versus Bleeding Risk of Vitamin-K Antagonists: A Double-Edged Sword in Patients with Atrial Fibrillation Who Require Surgery

Dobromir Dobrev

Cardiovascular Therapeutics, 2009

View PDFchevron_right

Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents

Jean Pierre Bassand

Europace, 2012

View PDFchevron_right

Non-vitamin K antagonist anticoagulants to cardio embolic ischemic stroke due to atrial fibrillation: a brief update to clinical practice

Richard M . Montgomery

Perspectivas Médicas, 2016

View PDFchevron_right

Assessing Safety of Direct Thrombin Inhibitors, Direct Factor Xa Inhibitors and Vitamin K Antagonists in Patients with Atrial Fibrillation: A Nation-Wide Propensity Score Matched Cohort from Sweden

Marie Linder

Clinical Epidemiology

View PDFchevron_right

Oral anticoagulant use for stroke prevention in atrial fibrillation patients with difficult scenarios

Jennifer Jeanne Vicera

IJC Heart & Vasculature, 2018

View PDFchevron_right